Needham upgrades Optimer Pharmaceuticals Inc. (Nasdaq: OPTR) from Hold to Buy with a $19 price target. The firm ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE